Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus NORCEPT E 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus NORCEPT E 1 35 21.
LOESTRIN 21 1.5/30 vs NORCEPT-E 1/35 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
None Documented
None Documented
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive